1. Home
  2. |Insights
  3. |Crowell & Moring Represents Third Rock Ventures in $108 Million Series C Financing for Terremoto Biosciences

Crowell & Moring Represents Third Rock Ventures in $108 Million Series C Financing for Terremoto Biosciences

Firm News | less than 1 min read | 04.15.26

Boston and San Francisco – April 15, 2026: Crowell & Moring represented investor Third Rock Ventures in the closing of a $108 million Series C financing round for Terremoto Biosciences, a biotechnology company developing highly targeted, small molecule medicines.  

Along with Third Rock, the financing included support from existing investors OrbiMed, Novo Holdings, and Cormorant Asset Management, LP, as well as from new investors RA Capital Management, Deep Track Capital, Osage University Partners (OUP), and BeOne Medicines. Proceeds from the financing will enable Terremoto to advance its selective AKT1 inhibitor programs through Phase 1 clinical development for patients with cancer and rare diseases such as hereditary hemorrhagic telangiectasia. 

The financing transaction was led by partner Kurt Machemer (Boston). 


Insights

Firm News | 3 min read | 10.01.26

Crowell & Moring Elects New Chair

Washington, D.C. – October 1, 2026: Crowell & Moring today announced that Glen McGorty, a member of the firm’s Management Board and Executive Committee, Chair of the Litigation and Trial Department, and managing partner of its New York office, has been elected by the partnership to be the next chair of the firm’s Management Board. His three-year term will begin March 1, 2027. McGorty will be the first chair in the firm’s history to be based outside of Washington, D.C....

View All Insights